Abbott Labs

ABT-N

NYSE:ABT

94.92
2.82 (3.06%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
BUY
BUY
May 31, 2013

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 31, 2013

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

PAST TOP PICK
PAST TOP PICK
May 9, 2013

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out. This is about the best performing part of the market this year. Good dividend growth and very strong balance sheets.

Show full opinionHide full opinion

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out. This is about the best performing part of the market this year. Good dividend growth and very strong balance sheets.

PAST TOP PICK
PAST TOP PICK
April 15, 2013

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 15, 2013

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

BUY
BUY
April 9, 2013

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 9, 2013

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

BUY
BUY
March 7, 2013

Just initiated 3.6% dividend. Does like it. They may put growth back into business model or you have an activist shareholder that puts them up for sale. If stock stays flat you will collect the divided.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
March 7, 2013

Just initiated 3.6% dividend. Does like it. They may put growth back into business model or you have an activist shareholder that puts them up for sale. If stock stays flat you will collect the divided.

COMMENT
COMMENT
February 26, 2013

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 26, 2013

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

BUY
BUY
February 25, 2013

She sold ABv. But ABT-N has a very good basic business. Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 25, 2013

She sold ABv. But ABT-N has a very good basic business. Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon.

TOP PICK
TOP PICK
February 12, 2013

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 12, 2013

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

COMMENT
COMMENT
February 5, 2013

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 5, 2013

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

HOLD
HOLD
January 10, 2013

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 10, 2013

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

BUY
BUY
December 3, 2012

It already had a bump up in price, but he is planning on holding both parts. Buying for new clients.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
December 3, 2012

It already had a bump up in price, but he is planning on holding both parts. Buying for new clients.

TOP PICK
TOP PICK
November 30, 2012

Splitting as of Jan 2nd. Trading ‘as is’ in December. ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks. Thinks there is more upside in the Drug exploration part. Humera is one of the 5 biggest drugs globally. 5 drugs in clinical trials. A really good pipeline.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 30, 2012

Splitting as of Jan 2nd. Trading ‘as is’ in December. ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks. Thinks there is more upside in the Drug exploration part. Humera is one of the 5 biggest drugs globally. 5 drugs in clinical trials. A really good pipeline.

TOP PICK
TOP PICK
November 26, 2012

You can buy at its model price and when the company splits up it would increase value. The balance sheet has high growth parts buried within it. These smaller parts create more value. The pieces are worth more than the whole. 40 increases in dividends and very shareholder friendly. He would stay with both after the split until you can review balance sheets.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 26, 2012

You can buy at its model price and when the company splits up it would increase value. The balance sheet has high growth parts buried within it. These smaller parts create more value. The pieces are worth more than the whole. 40 increases in dividends and very shareholder friendly. He would stay with both after the split until you can review balance sheets.

SELL
SELL
November 21, 2012

(Market Call Minute) Would sell on the split. It is too complicated to be there with the split.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 21, 2012

(Market Call Minute) Would sell on the split. It is too complicated to be there with the split.

TOP PICK
TOP PICK
November 19, 2012

12 drugs under patent after a current one comes off patent. A hepatitis drug is about to come out as well. It could hit its 52 week high.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 19, 2012

12 drugs under patent after a current one comes off patent. A hepatitis drug is about to come out as well. It could hit its 52 week high.

Showing 61 to 75 of 122 entries